Navigation Links
Novavax Reports Second Quarter 2009 Financial Results

oration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

                                   NOVAVAX, INC.
               (in thousands, except share and per share information)

                                    Three months ended      Six months ended
                                        June 30,                June 30,
                                        --------                --------
                                    2009      2008          2009       2008
                                    ----      ----          ----       ----
    Revenues                           29        342           50         800
                                       --        ---           --         ---

    Operating costs and
       Research and development     5,297      5,380        9,563     
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
2. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
4. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
5. Novavax Announces Repayment of $5 Million of Convertible Debt
6. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
7. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
8. Novavax Appoints Stanley Erck to Board of Directors
9. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
10. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
11. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  Sigma-Aldrich Corporation (NASDAQ: ... ® brand within its Applied Diagnostics and ... acid reference standards product line with ten certified ... tested bile acids and their stable-labeled internal standards. ... of lithocholic acid, taurocholic acid and native and ...
(Date:10/8/2015)... ... October 08, 2015 , ... ProMIS Neurosciences, ... agreement to develop and commercialize intellectual property rights belonging to The University of ... 2009, and affords exclusive worldwide rights to intellectual property based on use of ...
(Date:10/7/2015)... PUNE, India , October 8, 2015 ... --> Medical biotechnology accounts for ... use of bioinformatics in drug discovery and ... with . ... --> On the basis of applications, ...
(Date:10/7/2015)... ... October 07, 2015 , ... Neil Riordan, PhD to Discuss ... Tomorrow, October 8th, at Mar-a-Lago from 3:50 pm to 4:30 pm. , Dr. Riordan ... therapy. , He is the Co-Founder and Chief Science Officer of the ...
Breaking Biology Technology:
... the first time observed chemical reactions near absolute zero, ... that reaction rates can be controlled using quantum mechanics, ... results and techniques, described in the Feb. 12 issue ... unknown aspects of how molecules interact, a key to ...
... , CINCINNATI , ... it will release its fourth quarter and full-year 2009 financial results after ... will host a telephone conference call and simultaneous webcast on Thursday, ... and answer session will follow. , Conference Call Instructions ...
... , , , ... /PRNewswire-Asia/ -- The January issue of,"Neuropharmacology", publishes the article ... (MLC 601) protective effects on neuronal and brain,injuries as well ... The French research team was led by Prof. ...
Cached Biology Technology:
(Date:10/5/2015)... 2015 ) ... Inc. (NASDAQ: NXTD ), a biometric authentication company ... ) releases the following market ... ), a biometric authentication company focused on the growing ... ( ) releases the following market ...
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court of ... another key ruling in favor of Crossmatch ™, ... fingerprint scanner company Suprema and its U.S. partner Mentalix ... a trade provision that declares it unlawful to engage ... infringing two of Crossmatch,s patents, the 5,900,993 patent and ...
(Date:9/28/2015)... 28, 2015 CLEAR, the leading ... expedited traveler service is coming to Austin-Bergstrom ... bringing a frictionless experience, serious speed and ... "CLEAR offers our travelers an expedited security ... Jim Smith , Executive Director, Austin-Bergstrom ...
Breaking Biology News(10 mins):
... more species in the tropics than in the temperate regions ... the tropics (perhaps more than half), but the reason has ... researchers have hypothesized that climatic factors somehow cause species to ... in the November issue of The American Naturalist, John Wiens ...
... the ironic name "Srcasm" can counteract the effects of ... by investigators at the University of Pennsylvania School of ... acts like a brake in epithelial cells, preventing uncontrolled ... Src kinases. This finding, published online in the Journal ...
... been a key factor in why the human brain ... a study comparing the genomes of humans, chimpanzees, mice ... Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) and Joint ... genetic differences in DNA sequences that appear to regulate ...
Cached Biology News:
Request Info...
... Maintenance 112 days/each , ... injections x5 /each , Test ... Production bleed (25 ml blood =12 ml serum) ... blood (~50 ml serum) x1 each , free ...
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
chk 1 kinase...
Biology Products: